(Q46626206)

English

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, pla

scientific article published on 29 August 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, pla (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

author name string

P Vuylsteke

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

M Huizing

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

K Petrakova

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

R Roylance

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

R Laing

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

F Abell

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

S Gendreau

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

I Rooney

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

D Apt

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

J Zhou

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

S Singel

12

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

L Fehrenbacher

13

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

publication date

29 August 2016

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

Annals of Oncology

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

27

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

2059-2066

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Breast Cancer Version 2.2015.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW320

21 January 2018

Identifiers

10.1093/ANNONC/MDW320

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/27573562

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46626206&oldid=1672299786"